Allies promote MRI-guided treatment

Article

Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused

Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused ultrasound, an investigational method of heating and destroying tumors or tissue such as uterine fibroids with millimeter precision. The collaboration will initially focus on preclinical studies leading to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston. Epix and InSightec will share information on their technologies to optimize the use of contrast agents during interventional procedures.

© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 4.

Recent Videos
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
Related Content
© 2025 MJH Life Sciences

All rights reserved.